Alexandra Evagelidis

Montreal, QC H2W1R7, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Corrigendum to "Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights" [J Clin Lipidol (2026) S1933-2874(26)00045-0, ahead of print].

Corrigendum to "Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights" [J Clin Lipidol (2026) S1933-2874(26)00045-0, ahead of print].

Journal: Journal of clinical lipidology

Published: April 23, 2026

Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights.

Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights.

Journal: Journal of clinical lipidology

Published: December 15, 2025

Shedding of GPP130 by PC7 and Furin: Potential Implication in Lung Cancer Progression.

Shedding of GPP130 by PC7 and Furin: Potential Implication in Lung Cancer Progression.

Journal: International journal of molecular sciences

Published: May 21, 2025

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human.

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human.

Journal: Journal for immunotherapy of cancer

Published: May 15, 2025

Corrigendum to "PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease" [Metabolism Volume 150, January 2024, 155736, PMID: 7967646].

Corrigendum to "PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease" [Metabolism Volume 150, January 2024, 155736, PMID: 7967646].

Journal: Metabolism: clinical and experimental

Published: September 19, 2024

Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C.

Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C.

Journal: Cells

Published: March 14, 2024

PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease.

PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease.

Journal: Metabolism: clinical and experimental

Published: April 21, 2023

SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2.

SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2.

Journal: Viruses

Published: December 15, 2022

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels.

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels.

Journal: Molecular metabolism

Published: October 05, 2022

Erratum for Essalmani et al., "Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity".

Erratum for Essalmani et al., "Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity".

Journal: Journal of virology

Published: June 06, 2022

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.

Journal: Journal of virology

Published: March 28, 2022

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.

Journal: The Journal of biological chemistry

Published: April 08, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026